Patent · US Active

Anthracycline-based antibody drug conjugates having high in vivo tolerability

US10758556B2 · kind B2 · utility

1Cited by
13References
31Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 6, 2019
Grant dateSep 1, 2020
Priority date—
Expiry dateAug 6, 2039

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/55
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention relates to antibody drug conjugates (ADCs) presenting improved properties of in vivo tolerability.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.